Lost password ?
<< Back to Equity Research
Gulf Pharmaceutical
JULPHAR, NEW CATALYSTS ARE HERE
Feb 13 - Julphar (Buy, UAE) has been in a downward trend since long months ago losing around 48.6% compared to its three-year high reached in late August 2021. Meanwhile, the news flow was rather positive led ...
Executive summary
Conflict of Interest
Pages 40
Language English
Publish on February 13, 2023
€ 500
VAT Exl.
You might be also interested by these reports :
Apr 15 PM
Idea Kicker
JULPHAR, WAITING FOR A SAFETY MARGIN
Mar 19 AM
Gulf Pharmaceutical
A better Q4 lifted our Target Price
Mar 16 PM
Gulf Pharmaceutical
A hit from outside GCC revenues in 2023
Mar 04 PM
Gulf Pharmaceutical
Modest 2023 results despite a better-than-expected Q4
FIND A REPORT
CONCEPT
Each company is researched in depth using a structured robust and transparent process.

AlphaMena provides analyses based upon exhaustive and homogeneous information which allows to compare stocks geographically, sector-wise, and by thematic.

The analyses include actuarial as well as off balance-sheet data.
BloombergStarmineFactsetReutersCapital IQ